Astellas US LLC et al v. Baxter Healthcare Corporation
| Astellas US LLC, Astellas Pharma US, Inc. and Gilead Sciences, Inc. |
| Baxter Healthcare Corporation |
| 1:2022cv01390 |
| October 24, 2022 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on November 15, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 8 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Plaintiff's Complaint to January 16, 2023 - filed by Baxter Healthcare Corporation. (Rovner, Philip) |
SO ORDERED, re #8 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Plaintiff's Complaint to January 16, 2023 filed by Baxter Healthcare Corporation. Reset Answer Deadlines: Baxter Healthcare Corporation answer due 1/16/2023. Ordered by Judge Colm F. Connolly on 11/15/2022. (kmd)
|
| Filing 7 SUMMONS Returned Executed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc..Baxter Healthcare Corporation served on 10/27/2022, answer due 11/17/2022. (Del Dotto, Kelly) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (nms) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (vfm) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas US Holding, Inc for Astellas Pharma US, Inc., Astella Pharma Inc. for Astella Pharma US, Inc. Astellas US LLC filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (vfm) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,106,183 ;US RE 47,301 E ;US 8,524,883. (vfm) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/12/2022. Date of Expiration of Patent: 02/02/2027.Thirty Month Stay Deadline: 3/12/2025. (vfm) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) |
| Filing 1 COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Baxter Healthcare Corporation ( Filing fee $ 402, receipt number ADEDC-3989026.) - filed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Civil Cover Sheet) (vfm) |
| No Summons Issued. (vfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
